Rabbits have a unique immune system which allows them to develop antibodies against small epitopes present in small molecules, lipids and polymers or subtle changes in epitopes such as post-translational modifications or single amino acid substitutions. RabMAb® primary antibodies offer high affinity and specificity to the modified target with minimal cross-reactivity to the non-modified site.
The ability of rabbit antibodies to recognize small epitopes translates to success with recognition of post-translational modifications (e.g. phosphorylation, methylation, acetylation, sumoylation). In addition, many small compounds and peptides do not elicit a good immune response in mice but do so in rabbits.
We now offer over 500 post-translational modification specific antibodies and have more in the pipeline. We also have the ability to generate custom RabMAb primary antibodies against challenging targets. Our Custom Services team has a demonstrated record of success developing antibodies to post-translational modifications (PTMs).
The data below from the lab of Dr. Ogut, Division of Cardiovascular Disease, Mayo Clinic demonstrates the RI alpha phospho-specific antibody validation. These two RabMAb primary antibodies specific for Ser77 and Ser83 phosphorylated RI alpha were developed using our RabMAb technology.
Reprinted from Archives of Biochemistry and Biophysics, 538 /1, Han YS, Arroyo J, Ogut O., Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state., 25-33., Copyright (2013), with permission from Elsevier.